Very light in detail
Sydney, Australia, 2 May 2022: Imugene (ASX: IMU) today announced termination of its
supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA.
Imugene is continuing with its clinical trial to evaluate the safety and efficacy with the use of
Imugene’s HER-Vaxx, a B-cell activating immunotherapy in patients with HER-2 positive
gastric cancer in combination with anti-PD-1 therapy.
Ann: Termination of Supply Agreement, page-4
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
-0.001(1.43%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.9¢ | $357.0K | 5.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 2110214 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 1427559 | 9 |
View Market Depth
| Last trade - 11.54am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
-0.001 ( 0.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.1¢ | 6.9¢ | 2691148 | ||
| Last updated 12.14pm 27/05/2024 ? | |||||
| IMU (ASX) Chart |